NCT03926013View on ClinicalTrials.gov

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

August 23, 2021

Study Completion Date

September 2, 2021

Conditions
Neoplasms
Interventions
DRUG

JNJ-63898081

JNJ-63898081 will be administered.

Trial Locations (7)

10032

Columbia University Medical Center, New York

20892

NIH Clinical Center, Bethesda

84112

University of Utah, Salt Lake City

94158

University of California, San Francisco, San Francisco

98195-9472

University of Washington, Seattle

V5Z4E6

British Columbia Cancer Agency, Vancouver

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03926013 - A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Biotech Hunter | Biotech Hunter